Furthermore, the increased expression of PRAME is a marker of poor prognosis in different types of neoplasias, namely, breast cancer [131], head and neck squamous cell carcinoma (HNSCC) [132], neuroblastoma [133], osteosarcoma [134], among others. Here, PRAME is linked to neoplasm.